OUP user menu

B-Cell Lymphomas With Coexpression of CD5 and CD10

Henry Y. Dong MD, PhD, Wojciech Gorczyca MD, PhD, Zach Liu MD, Patricia Tsang MD, C. Daniel Wu MD, Patti Cohen MD, James Weisberger MD
DOI: http://dx.doi.org/10.1309/U98ADVKUC26R2RJA 218-230 First published online: 1 February 2003


Coexpression of CD5 and CD10 is highly unusual in B-cell lymphomas and may pose a diagnostic challenge. We report 42 cases of B-cell lymphoma with simultaneous expression of CD5 and CD10. They made up approximately 0.4% of all B-cell lymphomas seen during the study period and included the following cases: large B-cell lymphoma (LBCL), 14 (33%); follicular lymphoma (FL), 10 (24%); mantle cell lymphoma (MCL), 9 (21%); chronic lymphocytic leukemia, 4 (10%); acute precursor B-cell lymphoblastic leukemia/lymphoma, 2 (5%); and other low-grade B-cell lymphomas, 3 (7%). All MCLs had overexpression of bcl-1 or the t(11;14) and were CD43+. All FLs had typical histomorphologic features and were bcl-2+ and bcl-6+ but CD43−. Of 14 LBCLs, 5 were histologically high-grade. Six (43%) of 14 patients with LBCL died within 10 months of diagnosis of CD5+CD10+ lymphoma (median survival, 4 months), including all 3 patients with stage IV disease and 2 of 5 with histologically high-grade lymphoma. Our findings indicate that coexpression of CD5 and CD10 is rare but occurs in diverse subtypes of B-cell lymphoma. Investigation of bcl-1, bcl-6, and CD43 and morphologic evaluation may resolve the potential confusion in diagnosis and lead to the recognition of the correct lymphoma subtype.

Key Words:
  • B-cell lymphoma
  • Classification
  • Flow cytometry
  • Immunohistochemistry
  • CD5
  • CD10
  • bcl-1
  • bcl-6
  • Coexpression